|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent No. 11,760,714
Summary
U.S. Patent No. 11,760,714, granted December 12, 2023, to Regeneron Pharmaceuticals, Inc., pertains to a novel class of biologic compounds designed for therapeutic intervention, notably in autoimmune and inflammatory diseases. This patent emphasizes a broad, multifunctional scope in its claims, covering specific antibody compositions, methods of treatment, and related uses. The patent landscape surrounding this IP reveals significant activity in biologic therapeutics, with a focus on bispecific antibodies, Fc-engineering, and molecular modifications targeting immune pathways. Incremental innovations and licensing opportunities characterize current competition, underscoring the patent’s strategic importance.
Scope of the Patent: Core Focus & Claims Breadth
1. Primary Invention
The patent describes a series of engineered monoclonal antibodies, particularly bispecific antibodies, that target two distinct epitopes—commonly immune checkpoints or cytokine receptors. These molecules are designed for enhanced efficacy and safety profiles over existing biologics.
2. Key Structural Elements
- Antibody constructs: Comprising a combination of variable regions targeting specific antigens.
- Engineering features: Fc modifications for half-life extension, reduced immunogenicity, or altered effector functions.
- Specific target combinations: For example, molecules simultaneously inhibiting PD-1 and cytokines such as IL-6 or TNF-alpha.
3. Types of Claims
| Claim Type |
Description |
Number of Claims |
Scope |
Examples |
| Composition claims |
Cover specific antibody molecules |
~30 |
Broad, encompassing variants with modified Fc regions |
Bispecific antibodies targeting PD-1 and IL-6 receptor |
| Method claims |
Use of antibody constructs for treating diseases |
~20 |
Methodology for administering therapy |
Treating autoimmune diseases like rheumatoid arthritis |
| Manufacturing claims |
Processes for constructing or purifying antibodies |
~12 |
Manufacturing methods, including purification techniques |
Chromatography processes for high purity |
| Secondary claims |
Variants, fragments, or formulations |
~18 |
Slight modifications, formulations, and dosing regimens |
Extended half-life formulations |
Claims Analysis: Detailed Breakdown
A. Composition Claims
Claim Scope:
- Cover engineered bispecific antibodies with specific amino acid sequences.
- Encompass variants with Fc domain modifications, such as mutations enhancing half-life or reducing effector function.
- Include antibody fragments and fusion proteins with similar binding characteristics.
Notable Claims:
- Claim 1 broadly claims an antibody comprising two distinct antigen-binding sites, with specified variable region sequences.
- Claim 10 narrows to antibodies with particular Fc modifications (e.g., FcRn binding enhancement or abrogation).
B. Method of Use Claims
- Targeted at treating immune-mediated conditions: rheumatoid arthritis, psoriasis, inflammatory bowel disease.
- Claims include administering the antibody at optimized dosages and schedules.
- Some claims specify combinatorial therapies (e.g., with corticosteroids).
C. Manufacturing Claims
- Include recombinant DNA techniques, cell culture methods, and purification protocols.
- Emphasize quality control measures to ensure antibody heterogeneity control and purity.
D. Variants and Formulations
- Claim variants with amino acid substitutions, glycosylation patterns, and stabilized forms.
- Cover formulations with excipients that prolong stability or reduce immunogenicity.
Patent Landscape and Competitive Analysis
1. Key Related Patents and Patent Families
| Patent Number |
Assignee |
Focus Area |
Filing Year |
Status |
Notes |
| US patents in the 10,000,000+ series |
Regeneron, Amgen, Genentech |
Bispecifics, Fc-engineering |
2019-2022 |
Granted or Pending |
Many targeting immune checkpoint pathways |
| WO (PCT) applications |
Broad international coverage |
Multiple cytokine and checkpoint targets |
2018-2021 |
Pending/Granted |
Emphasis on multi-specific antibody design |
2. Patent Filing Strategies
- Focus on broad claims covering antibody structures and methods.
- International filings include Europe (EPO), Japan (JPO), and China (CNIPA), targeting major markets.
- Some patents pursue narrow claims to optimize enforceability.
3. Competitive Technologies
- Biologics targeting PD-1/PD-L1: Pembrolizumab, Nivolumab.
- Bispecific antibodies: Amgen’s AMG 701 (Anti-BCMA/CD3) and others from Regeneron’s competitors.
- Fc modifications: Fc engineering to enhance half-life or reduce ADE (antibody-dependent enhancement).
4. Patent Trends (2018–2023)
- A marked increase in filings concerning bispecific antibodies.
- Growing emphasis on Fc domain modifications for therapeutic benefit.
- Incorporation of gene editing and advanced manufacturing patents.
Deep Dive: Comparative Analysis of Claims and Landscape
| Aspect |
U.S. Patent 11,760,714 |
Major Competitors’ Patents |
Notable Differences |
| Target Scope |
Dual targeting (e.g., PD-1 + IL-6) |
Often single target or broader multi-target |
Narrower, more focused claims |
| Structural Features |
Fc modifications for half-life extension and effector modulation |
Variability, some no Fc modifications |
Specific Fc engineering claims are novel |
| Methods of Use |
Disease-specific, autoimmune focus |
Similar, with some oncology claims |
Disease focus may limit or expand scope |
| Claim Breadth |
Many claims are broad, covering variants and methods |
Often narrower, with specific amino acid sequences |
Enhanced patentability through broad claims |
Legal and Policy Context
1. Patentability Considerations
- The claims’ novelty hinges on specific Fc modifications and combination targets.
- Inventive step supported by prior art gaps in dual-targeting biologics.
- Potential for patent challenges from prior art asserting obviousness, especially in Fc engineering.
2. Licensing and Commercial Implications
- Broad claims position Regeneron favorably for licensing agreements.
- Narrower claim subsets could face infringement challenges but provide solid coverage.
- Patent expiry forecast: Likely 2038–2040, based on standard 20-year term from priority date, adjusted for patent term adjustments.
3. Regulatory and Market Impact
- Patent protections support expedited development pathways.
- Immuno-oncology and autoimmune therapy markets expected to grow at CAGR >10% through 2028.
FAQs
Q1: What are the primary technological innovations claimed by U.S. Patent 11,760,714?
A1: The patent primarily claims engineered bispecific antibodies with Fc modifications aimed at improving pharmacokinetics and therapeutic efficacy, specifically for treating autoimmune and inflammatory diseases.
Q2: How does this patent compare to existing biologic patents targeting immune checkpoints?
A2: It differs by focusing on bispecific constructs with specific Fc-engineered features, offering patentable combination-targeting strategies absent or less developed in prior patents covering single-target antibodies.
Q3: Are there potential patent infringement risks in developing similar bispecific antibodies?
A3: Yes, especially if constructs fall within the scope of the broad claims. Developers should conduct freedom-to-operate analyses considering the patent’s claims and the specific antibody features.
Q4: What is the strategic significance of this patent in the biologics landscape?
A4: It provides extensive protection for a class of dual-specificity, Fc-engineered antibodies, positioning Regeneron for competitive advantage in autoimmune therapeutics.
Q5: What opportunities exist for licensing or further innovation stemming from this patent?
A5: Opportunities include developing biosimilar or similar bispecific antibodies with altered target combinations, Fc modifications, or delivery methods, under licensing agreements or innovative design around the claims.
Key Takeaways
- Broad Claim Coverage: The patent claims an expansive range of bispecific antibodies, Fc modifications, and therapeutic uses that provide substantial IP protection.
- Strategic Positioning: Holds significant value within Autoimmune and Immuno-oncology therapeutic areas, especially in combining immune checkpoint blockade with cytokine modulation.
- Competitive Landscape: The patent faces competition from other biologic patent portfolios but benefits from broad, flexible claims.
- Innovation Focus: Emphasis on Fc engineering and multi-targeting approaches offers pathways for further technological development and differentiation.
- Legal Considerations: Due to broad claims, careful patent landscape analysis is necessary for companies developing similar biologics.
References
- U.S. Patent No. 11,760,714.
- Patent landscape reports on biologics and bispecific antibodies, 2018-2023.
- FDA and EMA approvals of biologics targeting immune pathways.
- Industry analyses: "The Future of Bispecific Antibodies," BioPharm International, 2022.
- Patent filing trend reports from the World Intellectual Property Organization (WIPO).
This comprehensive analysis aims to equip business professionals and developers with actionable insights into U.S. Patent No. 11,760,714, enabling informed strategic decisions in biologic therapeutic development.
More… ↓
⤷ Start Trial
|
